NSYNC entertainer diagnosed with rare form of diabetes that happens in adulthood but is more like Type 1 than Type 2.
Investor's Business Daily on MSN6d
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't WorriedDexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...
Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of DexCom in a research note issued to ...
The year-over-year revenue growth was driven by strong new patient performance and the expanded availability of its G7 and DexCom ONE+ product platforms. Following the earnings release ...
She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups. However ...
In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback